GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Micro Biosystems Inc (NAS:RPID) » Definitions » Net Income

RPID (Rapid Micro Biosystems) Net Income : $-46.89 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rapid Micro Biosystems Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Rapid Micro Biosystems's Net Income for the three months ended in Dec. 2024 was $-9.67 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-46.89 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Rapid Micro Biosystems's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.22.


Rapid Micro Biosystems Net Income Historical Data

The historical data trend for Rapid Micro Biosystems's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Micro Biosystems Net Income Chart

Rapid Micro Biosystems Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income
Get a 7-Day Free Trial -37.08 -73.52 -60.81 -52.47 -46.89

Rapid Micro Biosystems Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.17 -13.32 -12.58 -11.32 -9.67

Rapid Micro Biosystems Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Rapid Micro Biosystems's Net Income for the fiscal year that ended in Dec. 2024 is calculated as

Net Income(A: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-46.867+-0.022+0+-7.105427357601E-15
=-46.89

Rapid Micro Biosystems's Net Income for the quarter that ended in Dec. 2024 is calculated as

Net Income(Q: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-9.675+0.009+0+0
=-9.67

Net Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rapid Micro Biosystems  (NAS:RPID) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Rapid Micro Biosystems's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Rapid Micro Biosystems Net Income Related Terms

Thank you for viewing the detailed overview of Rapid Micro Biosystems's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Micro Biosystems Business Description

Traded in Other Exchanges
N/A
Address
1001 Pawtucket Boulevard West, Suite 280, Lowell, MA, USA, 01854
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Executives
Melinda Litherland Pei director 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Sean M Wirtjes officer: Chief Financial Officer C/O VARIAN, INC., 3120 HANSEN WAY, M/S D-083, PALO ALTO CA 94304-1030
Spignesi Robert G. Jr. director, officer: President and CEO C/O RAPID MICRO BIOSYSTEMS, INC., 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854
Richard S Kollender director C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
Kennedy Lewis Capital Partners Master Fund Ii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Darren Richman 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Klm Gp Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Investment Management Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Management Lp 10 percent owner 225 LIBERTY STREET, SUITE 4210, NEW YORK NY 10281
David Chene 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Capital Partners Master Fund Iii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Iii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Investment Holdings Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120